Chimerix Investor Conference Presentation Deck

● Response Assessment Criteria for Glioma DMG with H3K27M typically have both enhancing and non-enhancing disease components RANO-HGG responses defined by decrease in enhancing disease RANO LGG response defined by decrease in T2 FLAIR RANO- HGG Criterion T1-Gd+ T2/FLAIR New lesion Corticosteroids Clinical status Requirement for response 8 CR None Stable or ↓ None None Stable or ↑ All PR ≥50%↓ Stable or ↓ None Stable or ↓ Stable or ↑ All T2- FLAIR SD <50% to <25% ↑ Stable or ↓ None Stable or ↓ Stable or ↑ All T1-Gd+ PD ≥25% t ↑t Presentt NA+ ++ Any+ Zoom

View entire presentation